In a large ATTR-specific cohort, Schwarting et al. evaluated RV–PA coupling in patients with ATTR cardiac amyloidosis receiving transthyretin stabilizer therapy and identified a TAPSE/PASP cutoff of ≤0.382 mm/mmHg as optimal for mortality prediction. The gene discussed is TTR; the disease is cardiac amyloidosis.